S8139

Sulindac

≥98.0%

• Synonym(e): (Z)-5-Fluor-2-methyl-1-[p-(methylsulfinyl)-benzyliden]-inden-3-essigsäure
• Empirische Formel (Hill-System): C₂₀H₁₇FO₃S
• CAS-Nummer: 38194-50-2
• Molekulargewicht: 356.41
• NACRES: NA.77
• PubChem Substance ID: 57654635
• UNSPSC Code: 12161501
• EC Number: 253-819-2
• MDL number: MFCD00599589
• Assay: ≥98.0%
• Form: powder
• Quality level: 200

Eigenschaften

• InChI key: MLKXDPUZXIRXEP-MFOYZWKCSA-N
• InChI: 1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
• SMILES string: CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c3ccc(cc3)S(C)=O
• biological source: synthetic (organic)
• assay: ≥98.0%
• form: powder
• technique(s): HPLC: suitable, gas chromatography (GC): suitable
• solubility: methanol: 50 mg/mL
• application(s): forensics and toxicology; veterinary
• originator: Merck & Co., Inc., Kenilworth, NJ, U.S.
• Quality Level: 200
• Gene Information: human ... ALB(213), PTGS1(5742), PTGS2(5743)

Beschreibung

Application

Treatment of human colorectal cancer cell lines induces MRP1 and MRP3 but not other members of the MRP family. Reported to significantly increase the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and epirubicin), as well as teniposide, VP-16 and vincristine. Sulindac was tested for its effect on heat-induced denaturation of albumin in vitro²⁸ and its ability to bind to human plasma protein.²⁹

Biochem/physiol Actions

Nicht-steroid, entzündungshemmend; begünstigter COX-1-Inhibitor

Sulindac is non-steroidal anti-inflammatory drug and an analgesic that has antiproliferative and apoptotic effects. It inhibits the expression and activity of cyclooxygenase-2 in human colon cancer cells^25,26 and reduces tumor burden in adenomatous polyposis patients.²⁷

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H301,H317,H334,H361
• pcodes: P201 - P280 - P301 + P310 + P330 - P302 + P352
• Hazard Classifications: Acute Tox. 3 Oral - Repr. 2 - Resp. Sens. 1 - Skin Sens. 1
• Lagerklasse: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges